News

Revolution Medicines snags $100M to attack RAS-mutated cancers

Revolution Medicines raised $100 million in series C financing to advance a stable of drugs aiming at what it calls “frontier targets” in cancer. These include a program targeting KRAS mutations, which were previously considered undruggable.…

Read more

Press Release

REVOLUTION Medicines Closes $100 Million Financing to Advance Pipeline of Novel Therapies Addressing Frontier Targets in RAS-Dependent Cancers

REDWOOD CITY, CA – July 9, 2019 – REVOLUTION Medicines, Inc., a clinical-stage leader in the discovery and development of novel small molecule inhibitors of frontier oncology targets within notorious pathways, today announced the closing of a $100…

Read more

News

Abstract painter: ASCO's KRAS rollouts red Haring? Early brushwork pleases

Der, for his part, predicted clinical data would separate the pair better in terms of PK issues. He also highlighted early work by Redwood City, Calif.-based Revolution Medicines Inc., saying that the company’s effort “stands out from all the other…

Read more

Publication / Presentation

Press Release

REVOLUTION Medicines to Present at the J.P. Morgan Healthcare Conference on January 8, 2019

Redwood City, CA – January 3, 2019 – REVOLUTION Medicines, Inc., a biotechnology company that translates frontier oncology targets to outsmart cancer, today announced that it will make a presentation at the 37th Annual J.P. Morgan Healthcare…

Read more